Literature DB >> 21684556

Lower urinary tract changes in young adults using ketamine.

S K Mak1, M T Y Chan, W F Bower, S K H Yip, S S M Hou, B B B Wu, C Y Man.   

Abstract

PURPOSE: We identified the profile of lower urinary tract changes in ketamine users in the community. In addition, we identified the relative risks of dose, frequency of ingestion and duration of ketamine use for changes in lower urinary tract function.
MATERIALS AND METHODS: A mobile medical assessment service was established at specific youth centers, and subjects who were known to social workers and who had a history of ketamine use were invited to participate in health screening. Lower urinary tract function was evaluated using the Pelvic Pain, Urgency and Frequency questionnaire, and uroflowmetry and ultrasonography.
RESULTS: Use of ketamine more than 3 times weekly was significantly associated with lower voided volumes. Pelvic Pain, Urgency and Frequency questionnaire scores were significantly higher for ketamine use for more than 24 months compared to use for short durations (7.82 vs 6.00). The scores on the symptom and bother subscales of the Pelvic Pain, Urgency and Frequency questionnaire decreased progressively with increased duration of abstinence. For individuals after 1 year of abstinence the Pelvic Pain, Urgency and Frequency questionnaire scores were significantly lower and voided volumes were higher than those for active users.
CONCLUSIONS: Ketamine users with at least a 2-year habit of 3 or more hits per week have altered bladder function that can be recognized and that causes bother. These early functional changes have the potential to normalize after 1 year of ketamine abstinence. This study provides a basis for the development of health promotion material that can be used in the community by welfare workers seeking to encourage drug cessation.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21684556     DOI: 10.1016/j.juro.2011.03.108

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Acute and chronic toxicity pattern in ketamine abusers in Hong Kong.

Authors:  Chan Yiu-Cheung
Journal:  J Med Toxicol       Date:  2012-09

Review 2.  Ketamine for chronic pain: risks and benefits.

Authors:  Marieke Niesters; Christian Martini; Albert Dahan
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

3.  Multiorgan dysfunction related to chronic ketamine abuse.

Authors:  Joseph M Pappachan; Binu Raj; Sebastian Thomas; Fahmy W Hanna
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-07

4.  Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine.

Authors:  David M Wood; Susannah Davies; Malgorzata Puchnarewicz; Atholl Johnston; Paul I Dargan
Journal:  Eur J Clin Pharmacol       Date:  2011-12-29       Impact factor: 2.953

Review 5.  Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.

Authors:  Nina Schimmel; Joost J Breeksema; Sanne Y Smith-Apeldoorn; Jolien Veraart; Wim van den Brink; Robert A Schoevers
Journal:  Psychopharmacology (Berl)       Date:  2021-11-23       Impact factor: 4.530

Review 6.  Molecular Pathophysiology and Potential Therapeutic Strategies of Ketamine-Related Cystitis.

Authors:  Chin-Li Chen; Sheng-Tang Wu; Tai-Lung Cha; Guang-Huan Sun; En Meng
Journal:  Biology (Basel)       Date:  2022-03-24

Review 7.  Urological complications of illicit drug use.

Authors:  Sean C Skeldon; S Larry Goldenberg
Journal:  Nat Rev Urol       Date:  2014-02-18       Impact factor: 14.432

8.  Outcome Evaluation of a Short-Term Hospitalization and Community Support Program for People Who Abuse Ketamine.

Authors:  Andrew M H Siu; Flora S L Ko; S K Mak
Journal:  Front Psychiatry       Date:  2018-07-17       Impact factor: 4.157

9.  Potential Orphan Drug Therapy of Intravesical Liposomal Onabotulinumtoxin-A for Ketamine-Induced Cystitis by Mucosal Protection and Anti-inflammation in a Rat Model.

Authors:  Wei-Chia Lee; Chia-Hao Su; You-Lin Tain; Cheng-Nan Tsai; Chun-Chieh Yu; Yao-Chi Chuang
Journal:  Sci Rep       Date:  2018-04-11       Impact factor: 4.379

10.  Complete reversal of the clinical symptoms and image morphology of ketamine cystitis after intravesical hyaluronic acid instillation: A case report.

Authors:  Ying-Lun Ou; Chin-Yu Liu; Tai-Lung Cha; Sheng-Tang Wu; Chih-Wei Tsao
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.